What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Long-acting GHRH analog with Drug Affinity Complex
Vialdyne primary owner
This Vialdyne page is the primary SEO owner for buyers evaluating CJC-1295 with DAC through a pharmacy QA, clinic procurement, or regulated-sourcing workflow. It should answer whether the buyer can request a batch COA, release-test scope, destination-market review, and add-on documentation before moving into pricing or repeat inventory planning.
Overview
CJC-1295 with DAC is the long-acting member of the Modified GRF 1-29 family. The structural difference is a maleimido-propionyl group at Lys30 that reacts covalently with Cys34 of human serum albumin in vivo, the Drug Affinity Complex (DAC) mechanism that gives the SKU its name. The resulting peptide-albumin conjugate circulates with kinetics close to albumin itself, stretching plasma half-life from roughly 30 minutes (no-DAC) to about 6-8 days and supporting once-weekly dosing in both compounding and research contexts. Vialdyne releases CJC-1295 with DAC as the lyophilised acetate against a ≥99.0% main-peak HPLC specification. The DAC variant carries a more demanding analytical burden than the no-DAC form: the maleimido group has to remain intact at the labelled position to retain in vivo albumin-binding activity, and a partially hydrolysed maleimide passes the standard HPLC purity gate at near-identical retention time but is pharmacokinetically inactive. The standard release packet covers peak-integration RP-HPLC plus ESI-MS at the modified mass; an intact-maleimide reactivity assay using a reference thiol target (typically cysteine or N-acetyl-cysteine) is offered as a documented add-on and is the recommended qualification test both at first-time pharmacy onboarding and on any batch where stability comes into question. The DAC PK profile fits sustained-elevation GH preparations and weekly-dosing compounding workflows; for pulse-pharmacology contexts the no-DAC CJC-1295 SKU is the appropriate alternative.
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Sterile-filled vials are available with the full release packet (sterility, endotoxin, CCI); loose lyophilized powder ships with sequence verification.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Certificate of Analysis
Published released-batch COAs for CJC-1295 with DAC, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →CJC-1295 with DAC
VD260428-CD051 · 99.23%
VerifiedRequest full COA →CJC-1295 with DAC
VD260428-CD5052 · 99.17%
Regulatory note
Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Selected literature
Frequently asked questions
The whole point of the Drug Affinity Complex is a maleimide that stays covalent-reactive, and that reactive group is what suffers first under bad conditions. Keep the sealed lyophilised vial at -20 C, dry and away from repeated warming, because moisture ingress and thermal cycling both promote ring-opening hydrolysis to the inactive carboxylic acid. Reconstitute only at point of use, aliquot immediately into single-use volumes, and minimise time the working solution spends at ambient temperature. Since the hydrolysis product co-elutes near the intact species, disciplined cold storage is the primary defence, not something a downstream HPLC will rescue.
A reactivity assay against a reference thiol confirms the maleimide is functional, but a pharmacy still wants the conventional identity-and-purity set alongside it. Request RP-HPLC main-peak area, ESI-MS at the modified-backbone mass to confirm the maleimido-propionyl group sits at Lys30, and sequence confirmation of the GRF 1-29 core. Water content and counter-ion quantitation matter here too, because the conjugated-peptide mass feeds your net-peptide fill calculation. Bundling the thiol-reactivity result with these standard release data on one certificate gives receiving inspection a complete picture of both structure and DAC functionality.
Related peptides
Modified GRF 1-29 · GHRH analog
Ghrelin / GHSR pathway GH-release peptide
29-mer
GHRH 1-29 fragment
